Ask AI
ProCE Banner Activity

BREAKWATER: PFS From the Phase III Trial of 1L Encorafenib + Cetuximab + Chemotherapy vs SoC for BRAF V600E–Mutant mCRC

Conference Coverage
Slideset

In the randomized phase III BREAKWATER trial, encorafenib + cetuximab + mFOLFOX6 was associated with a statistically significant improvement in PFS and higher ORR, the coprimary endpoints, as well as improved OS vs SoC in previously untreated patients with BRAF V600E–mutant mCRC.

Released: June 04, 2025

Expiration: December 03, 2025

Share

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by educational grants from Daiichi Sankyo, Inc. and Genentech, a member of the Roche Group.

Daiichi Sankyo, Inc.

Genentech, a member of the Roche Group